Home Cart Sign in  
Chemical Structure| 1818885-28-7 Chemical Structure| 1818885-28-7

Structure of ARV-825
CAS No.: 1818885-28-7

Chemical Structure| 1818885-28-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

ARV-825 is a PROTAC that connects ligands for Cereblon and BRD4, binding to BD1 and BD2 of BRD4 with Kd values of 90 nM and 28 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of ARV-825

CAS No. :1818885-28-7
Formula : C46H47ClN8O9S
M.W : 923.43
SMILES Code : CC1=NN=C2N1C(SC(C)=C3C)=C3C(C4=CC=C(Cl)C=C4)=N[C@H]2CC(NC5=CC=C(OCCOCCOCCOCCNC6=C(C(N(C7CCC(NC7=O)=O)C8=O)=O)C8=CC=C6)C=C5)=O
MDL No. :MFCD29472237
InChI Key :RWLOGRLTDKDANT-TYIYNAFKSA-N
Pubchem ID :92044400

Safety of ARV-825

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of ARV-825

epigenetics

Isoform Comparison

Biological Activity

Target
  • BET

    BRD4 BD2, Kd:28 nM

    BRD4 BD1, Kd:90 nM

In Vitro:

Cell Line
Concentration Treated Time Description References
MDA-MB-231 0.4 μM 12, 24, or 48 hours ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells. PMC6717344
MDA-MB-231R 0.4 μM 12, 24, or 48 hours ARV-825 significantly reduced the expression levels of BET proteins BRD4 and BRD2, although the reduction of BRD4 was milder in the resistant cells. PMC6717344
MDA-MB-231 0.5 µM 24 h ARV-825 inhibits mammosphere formation in MDA-MB-231 cells and reduces CD44+/CD24- and ALDH expressing subpopulations. PMC10623882
HCC1937 0.1 µM 24 h ARV-825 inhibits mammosphere formation in HCC1937 cells and reduces ALDH expressing subpopulations. PMC10623882
SKO-007(J3) 0.2 μM 24 hours ARV-825 significantly downregulated IRF4 and cMYC expression and upregulated MICA expression. PMC5131470
LPS141 200 nM 24 hours To evaluate the anti-proliferative effect of ARV-825 on LPS141 cells, results showed that ARV-825 significantly inhibited cell proliferation. PMC6430783
MLS402 200 nM 24 hours To evaluate the anti-proliferative effect of ARV-825 on MLS402 cells, results showed that ARV-825 significantly inhibited cell proliferation. PMC6430783
SUP-T1 cells 20 nM 24 hours ARV-825 treatment resulted in downregulation of MYC and CD44 expression, along with decreased protein levels of NOTCH1, MYC, and CD44. PMC9061299
KOPT-K1 cells 50 nM 24 hours ARV-825 treatment led to significant downregulation of CD44 and CD44v8-10 mRNA and increased intracellular ROS levels. PMC9061299
SET2 cells 1.0 μM 24 hours To compare the effects of ARV-825 and OTX015 on the levels of BRD4 and BRD2 in sAML SET2 cells, the results showed that ARV-825 significantly reduced the levels of BRD4 and BRD2. PMC5537055
GL261 cells 0.0625 μg/ml 24 hours To evaluate the cytotoxicity of cRGD-P/ARV-DOX on GL261 cells, the results showed that cRGD-P/ARV-DOX had greater cytotoxicity to GL261 cells at 24 h and 48 h. PMC9489811
B16 cells 200 ng/mL 24 hours ARV-825 significantly reduced the viability of B16 cells, and MNC@Ca/MnCO3/ARV nanoparticles showed stronger cytotoxicity, significantly inducing ferroptosis in B16 cells. PMC11810845
DC2.4 cells 200 ng/mL 24 hours ARV-825 showed no significant toxicity to DC2.4 cells, indicating its safety for normal immune cells. PMC11810845
SKO-007(J3) 0.2 μM 48 hours ARV-825 significantly inhibited IRF4 and cMYC mRNA expression and upregulated MICA mRNA expression. PMC5131470
GL261 cells 100 ng/mL 48 hours To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle. PMC11672279
LN229 cells 100 ng/mL 48 hours To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle. PMC11672279
U251 cells 100 ng/mL 48 hours To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle. PMC11672279
U87 cells 100 ng/mL 48 hours To evaluate the effects of ARV-825 on cell proliferation, cell cycle, and apoptosis, results showed that ARV-825 significantly inhibited cell proliferation, induced apoptosis, and blocked the cell cycle. PMC11672279
UKE1 cells 256 ± 12.45 nM 48 hours To compare the effects of ARV-825 and OTX015 on apoptosis in UKE1 cells, the results showed that ARV-825 induced significant apoptosis at a concentration of 256 ± 12.45 nM. PMC5537055
U251 cells 0.125 μg/ml 48 hours To evaluate the cytotoxicity of cRGD-P/ARV-DOX on U251 cells, the results showed that cRGD-P/ARV-DOX had better synergetic anti-cancer effects at 48 h. PMC9489811
BT549 0.2, 0.4, and 1 μM 48 or 96 hours ARV-825 exhibited significant antiproliferative activity in BT549 cells. PMC6717344
SKOV3 0.2, 0.4, and 1 μM 48 or 96 hours ARV-825 exhibited significant antiproliferative activity in SKOV3 cells. PMC6717344
OVCAR3 0.2, 0.4, and 1 μM 48 or 96 hours ARV-825 exhibited significant antiproliferative activity in OVCAR3 cells. PMC6717344
Jurkat 1 μM 7 days ARV-825 significantly inhibited the proliferation of Jurkat cells and suppressed cell growth by inducing cell cycle arrest and apoptosis. PMC8061034
CCRF-CEM 1 μM 7 days ARV-825 significantly inhibited the proliferation of CCRF-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis. PMC8061034
Molt4 1 μM 7 days ARV-825 significantly inhibited the proliferation of Molt4 cells and suppressed cell growth by inducing cell cycle arrest and apoptosis. PMC8061034
6 T-CEM 1 μM 7 days ARV-825 significantly inhibited the proliferation of 6 T-CEM cells and suppressed cell growth by inducing cell cycle arrest and apoptosis. PMC8061034

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
NSG mice LPS141 xenograft model Intraperitoneal injection 5 mg/kg Once daily, 5 days per week, continuous treatment To evaluate the anti-tumor effect of ARV-825 on the LPS141 xenograft model, results showed that ARV-825 significantly delayed tumor growth and prolonged mouse survival. PMC6430783
Mice GL261 subcutaneous tumor model intravenously injected 10 mg/kg every two days for a total of four times To evaluate the antitumor efficacy of ARV-825 in vivo, results showed that ARV-825 significantly inhibited tumor growth and prolonged the survival of mice. PMC11672279
Mice T-ALL PDX model Intraperitoneal injection 5 mg/kg or 10 mg/kg Three times a week for several weeks ARV-825 treatment significantly reduced leukemia burden and prolonged the survival of mice. PMC9061299
C57BL/6 mice Subcutaneous glioma model Intravenous injection 2.5 mg/kg Every three days for three consecutive times To evaluate the anti-tumor efficacy of cRGD-P/ARV-DOX in the subcutaneous glioma model, the results showed that cRGD-P/ARV-DOX significantly inhibited tumor growth. PMC9489811
C57BL/6 mice Melanoma model IntratumOral injection 100 μL Injected on days 7, 11, and 15, continued until day 22 MNC@Ca/MnCO3/ARV/anti-PD1 nanoparticles significantly inhibited melanoma growth and enhanced anti-tumor immune responses, successfully constructing an in situ tumor vaccine. PMC11810845
Balb/c Nude mice TNBC tumor model intravenous injection 3.5 mg/kg every other day for a total of 5 times To evaluate the antitumor effect of ARV-MBs combined with ultrasound in the TNBC tumor model, the results showed that ARV-MBs combined with ultrasound significantly inhibited tumor growth, with a tumor inhibition rate of 81.4%. PMC11319668
Nude mice T-ALL xenograft model Intraperitoneal injection 10 mg/kg Once daily for 14 days ARV-825 significantly inhibited tumor growth in the T-ALL xenograft model and suppressed tumor proliferation by downregulating BRD4 and c-Myc protein expression. PMC8061034

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.08mL

0.22mL

0.11mL

5.41mL

1.08mL

0.54mL

10.83mL

2.17mL

1.08mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories